Hemarthroses Recurrent hemarthroses The importance of rapid bleeding control Hemophilia patients with inhibitors present a special challenge “The time taken to stop a bleeding episode is very important to the patient as it reduces the time a patient is in pain, the amount of hemostatic agent required, the potential long-term damage to the joint, and the subsequent cost of undergoing a joint arthroplasty. ” The vicious cycle of joint damage 8 In the long term, the presence of blood in the joint leads to chronic synovitis, development of a target joint, and progressive arthropathy 8 Difficult to manage 4,5,6 Poorer outcome following joint bleeds 7 Greater risk of long-term joint damage and disability 7 Delaying treatment results in: 10 - Longer time to bleeding resolution - A larger number of doses required to stop the bleeding - Increased costs Clinical guidelines for hemophilia emphasise the importance of early intervention NiaStase RT ® acts here NiaStase RT ® (eptacog alfa, activated) is indicated in hemophilia A/B patients with inhibitors to FVIII or FIX, respectively, for the treatment of bleeding episodes (including treatment and prevention of those occurring during and after surgery). 3 Long term efficacy has not been established.